Cor Vasa 2011, 53(1-2):39-43

Advances in differential diagnosis of cardiomyopathies

Miloą Kubánek1,*, Marek ©ramko1, Jana Vrbská1, Dana Kautznerová2
1 Klinika kardiologie
2 Oddělení radiodiagnostických metod, Institut klinické a experimentální medicíny, Praha, Česká republika

Development of the classification of cardiomyopathies evolves from a descriptive approach to identification of the causes of the disease. Advances in the fields of molecular genetics, imaging techniques, and evaluation of endomyocardial biopsy specimens have provided new insights into the etiology of individual types of cardiomyopathy. The paper seeks to assess the value of the above specialties and tools in current clinical practice.

Keywords: Hereditary cardiomyopathy; Cardiac magnetic resonance imaging; Endomyocardial biopsy; Cardiomyopathy

Published: January 1, 2011  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Kubánek M, ©ramko M, Vrbská J, Kautznerová D. Advances in differential diagnosis of cardiomyopathies. Cor Vasa. 2011;53(1-2):39-43.
Download citation

References

  1. Elliott P, Andersson B, Arbustini E, et al. Classification of the cardiomyopathies: a position statement from the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J 2008;29:270-276. Go to original source... Go to PubMed...
  2. Hershberger RE, Lindenfeld J, Mestroni L, et al. Genetic evaluation of cardiomyopathy - a Heart Failure Society of America Practice Guideline. J Card Fail 2009;15:83-97. Go to original source... Go to PubMed...
  3. Bos JM, Towbin JA, Ackerman MJ. Diagnostic, prognostic, and therapeutic implications of genetic testing for hypertrophic cardiomyopathy. J Am Coll Cardiol 2009;54:201-211. Go to original source... Go to PubMed...
  4. Čurila K, Pěnička M, Línková H, et al. Molekulární genetika u hypertrofické kardiomyopatie. Cor Vasa 2007;49:138-142. Go to original source...
  5. Binder J, Ommen SR, Gersh BJ, et al. Echocardiography-guided genetic testing in hypertrophic cardiomyopathy: septal morphological features predict the presence of myofilament mutations. Mayo Clin Proc 2006;81:459-467. Go to original source... Go to PubMed...
  6. Olivotto I, Girolami F, Ackerman MJ, et al. Myofilament protein gene mutation screening and outcome of patients with hypertrophic cardiomyopathy. Mayo Clin Proc 2008;83;630-638. Go to original source...
  7. Maron BJ. Contemporary insights and strategies for risk stratification and prevention of sudden death in hypertrophic cardiomyopathy. Circulation 2010;121:445-456. Go to original source... Go to PubMed...
  8. Judge DP. Use of genetics in the clinical evaluation of cardiomyopathy. JAMA 2009;302:2471-2476. Go to original source... Go to PubMed...
  9. Mehta A, Beck M, Elliott P, et al. Enzyme replacement therapy with galactosidase alfa in patients with Fabry's disease: an analysis of registry data. Lancet 2009;374:1986-1996. Go to original source... Go to PubMed...
  10. Linhart A, Kampmann C, Zamorano LT, et al. Cardiac manifestations of Anderson-Fabry disease: results from the international Fabry outcome survey. Eur Heart J 2007;28:1228-1235. Go to original source... Go to PubMed...
  11. Maron BJ, Roberts WC, Arad M, et al. Clinical outcome and phenotypic expression in LAMP2 cardiomyopathy. JAMA 2009;301:1253-1259. Go to original source... Go to PubMed...
  12. Charron P, Villard E, Sebillon P, et al. Danon's disease as a cause of hypertrophic cardiomyopathy: a systematic survey. Heart 2004;90:842-846. Go to original source... Go to PubMed...
  13. Kubánek M, Elleder M, Sikora J, et al. Danonova nemoc - porucha autofagie jako příčina hypertrofické kardiomyopatie. Cor Vasa 2010;52:706-712. Go to original source...
  14. Hoedemaekers YM, Caliskan K, Michels M, et al. The importance of genetic counseling, DNA diagnostics, and cardiologic family screening in left ventricular noncompaction cardiomyopathy. Circ Cardiovasc Genet 2010;3:232-239. Go to original source... Go to PubMed...
  15. Sechtem U, Mahrholdt H, Vogelsberg H. Cardiac magnetic resonance in myocardial disease. Heart 2007;93:1520-1527. Go to original source... Go to PubMed...
  16. McCrohon JA, Moon JC, Prasad SK, et al. Differentiation of heart failure related to dilated cardiomyopathy and coronary artery disease using gadolinium-enhanced cardiovascular magnetic resonance. Circulation 2003;108:54-59. Go to original source... Go to PubMed...
  17. Cooper LT. Myocarditis. N Engl J Med 2009;360:1526-1538. Go to original source... Go to PubMed...
  18. Friedrich MG, Sechtem U, Schulz-Menger J, et al. Cardiovascular magnetic resonance imaging in myocarditis: A JACC White Paper. J Am Coll Cardiol 2009;53:1475-1487. Go to original source... Go to PubMed...
  19. Syed IS, Glockner JF, Feng D. Role of cardiac magnetic resonance imaging in the detection of cardiac amyloidosis. JACC Cardiovasc Imaging 2010;3:155-164. Go to original source... Go to PubMed...
  20. Kuhl U, Pauschinger M, Noutsias M et al. High prevalence of viral genomes and multiple viral infections in the myocardium of adults with idiopathic left ventricular dysfunction. Circulation 2005;111:887-893. Go to original source... Go to PubMed...
  21. Dennert R, Velthuis S, Wolffs P, et al. Parvovirus B19 persists in normal and diseased hearts, but reactivates in failing hearts. Eur J Heart Fail 2010;9(S1):abstract.
  22. Bock CT, Klingel K, Kandolf R. Human parvovirus B19-associated myocarditis. N Engl J Med 2010;362:1248-1249. Go to original source... Go to PubMed...
  23. Kuhl U, Pauschinger M, Seeberg B, et al. Viral persistence in the myocardium is associated with progressive cardiac dysfunction. Circulation 2005;112:1965-1970. Go to original source... Go to PubMed...
  24. Kindermann I, Kindermann M, Kandolf R, et al. Predictors of outcome in patients with suspected myocarditis. Circulation 2008;118:639-648. Go to original source... Go to PubMed...
  25. Caforio AL, Calabrese F, Angelini A, et al. A prospective study of biopsy-proven myocarditis: prognostic relevance of clinical and aetiopathogenetic features at diagnosis. Eur Heart J 2007;28:1326-1333. Go to original source... Go to PubMed...
  26. Fu M. Inflammation in chronic heart failure: what is familiar, what is unfamiliar? Eur J Heart Fail 2009;11:111-112. Go to original source... Go to PubMed...
  27. Wojnicz R, Nowalany-Kozielska E, Wojciechowska C, et al. Randomized, placebo-controlled study for immunosuppressive treatment of inflammatory dilated cardiomyopathy: two-year follow-up. Circulation 2001; 104:39-45. Go to original source... Go to PubMed...
  28. Frustaci A, Chimenti C, Calabrese F, et al. Immunosuppressive therapy for active lymphocytic myocarditis: virological and immunologic profile of responders versus nonresponders. Circulation 2003;107:857-863. Go to original source... Go to PubMed...
  29. Frustaci A, Russo MA, Chimenti C. Randomized study on the efficacy of immunosuppressive therapy in patients with virus-negative inflammatory cardiomyopathy: the TIMIC study. Eur Heart J 2009;30:1995-2002. Go to original source... Go to PubMed...
  30. Maisch B, Pankuweit S, Koelsch S, et al; for the ESETCID Investigators. Sequential analysis of immunosuppressive therapy in autoreactive myocarditis - sequential analysis from ESETCID. Circulation 2007;116-II: 337-338. Go to original source...




Cor et Vasa

You are accessing a site intended for medical professionals, not the lay public. The site may also contain information that is intended only for persons authorized to prescribe and dispense medicinal products for human use.

I therefore confirm that I am a healthcare professional under Act 40/1995 Coll. as amended by later regulations and that I have read the definition of a healthcare professional.